← Back to Search

F-Fluciclovine PET/MR Scan for Brain Cancer

Q: Is fusion imaging in PET-MRI compliant with FDA regulations?

<p>The team at Power gives PET-<a href="https://www.withpower.com/clinical-trials/mri">MRI</a> a safety rating of 3, based on the amount of efficacy and safety data gathered from Phase 3 trials.</p>

Phase 3

Recruiting

Led By Michael Veronesi, MD, PhD

Research Sponsored by University of Wisconsin, Madison

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Has a brain metastasis diagnosis with at least one single visible contrast enhancing metastatic lesion on brain MRI

Currently receiving at least one immune checkpoint inhibitor for treatment of the malignancy

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 3 hours

Awards & highlights

Study Summary

This trial will use new imaging tech to see if it can better detect cancer in people with brain metastases. Participants will have two scans over 3 hours.

Who is the study for?

This trial is for adults over 18 with brain metastasis who are currently on immune checkpoint inhibitors. They must have had a visible lesion on a recent MRI and be able to lie still for imaging. Pregnant individuals, those unable to consent, or with allergies to the tracer or contraindications for PET/MRI cannot participate.Check my eligibility

What is being tested?

The study tests whether PET/MRI scans using an F-Fluciclovine radiotracer can better detect cancerous tissue in the brain compared to other imaging methods. Participants will undergo one combined PET/MRI scan and a separate MRI scan during about three hours of study participation.See study design

What are the potential side effects?

Potential side effects may include allergic reactions to the F-Fluciclovine radiotracer or discomfort from lying still during the scanning process. The specifics of any additional side effects related to this tracer aren't detailed here.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have a brain tumor that can be seen on an MRI.

Select...

I am currently being treated with a drug that boosts my immune system to fight cancer.

Select...

I am 18 years old or older.

Select...

I am willing and able to have a PET/MRI scan.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 3 hours

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~3 hours

This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 hours for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Amino acid uptake into tumor tissue

Cystolic protein in tumor cells

Trial Design

1Treatment groups

Experimental Treatment

Group I: PET-MRIExperimental Treatment1 Intervention

Participants will undergo F-Fluciclovine PET radiotracer and MRI

0 / 4Eligibility criteria met

Find a Location

Who is running the clinical trial?

University of Wisconsin, MadisonLead Sponsor

1,189 Previous Clinical Trials

3,169,501 Total Patients Enrolled

Blue Earth DiagnosticsIndustry Sponsor

38 Previous Clinical Trials

2,957 Total Patients Enrolled

Michael Veronesi, MD, PhDPrincipal InvestigatorUniversity of Wisconsin, Madison

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is fusion imaging in PET-MRI compliant with FDA regulations?

"The team at Power gives PET-MRI a safety rating of 3, based on the amount of efficacy and safety data gathered from Phase 3 trials."

Answered by AI

Are there current opportunities to enroll in this research effort?

"Records retrieved from clinicaltrials.gov show that, though initially listed on December 1st 2023 and last updated November 28th of the same year, this trial is not currently searching for participants. Nevertheless, there are 921 other medical studies open to new enrollees at present."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

18F-FLUC-CEST PET/MR in Patients With Brain Mets

2024. "18F-FLUC-CEST PET/MR in Patients With Brain Mets". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06159335.

All > Madison